GI
LXRX icon

Gradient Investments’s Lexicon Pharmaceuticals LXRX Stock Holding History

Gradient Investments’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-50
Closed -$1K – 770
2016
Q3 		$1K Buy
+50
New +$805 ﹤0.01% 658

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Gradient Investments's LXRX Position: Q4 2016 in Review

Gradient Investments sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2016, closing a stake of 50 shares — an estimated $1K sold.

Gradient Investments first reported a position in LXRX in Q3 2016 and held it in 1 quarter. The position peaked at $1K in Q3 2016. 146 funds tracked by Wall St. Rank hold LXRX as of Q4 2016.

  • Gradient Investments reported no remaining Lexicon Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Gradient Investments sold 50 Lexicon Pharmaceuticals shares in Q4 2016, an estimated $1K.
  • Gradient Investments first reported a position in Lexicon Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Gradient Investments's Lexicon Pharmaceuticals position peaked at $1K in Q3 2016.
  • 146 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2016.

Based on Gradient Investments's 13F filing for Q4 2016, filed 17 Jan 2017.